Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Can-Fite BioPharma Ltd (Can-Fite) is a clinical-stage drug development company that develops small molecule drugs for oncological, inflammatory, and metabolic diseases. The company’s pipeline products include Piclidenoson (CF101) for the treatment of psoriasis, Lowe syndrome, and canine osteoarthritis; Namodenoson (CF102) for liver cancer, pancreatic cancer, and metabolically associated steatohepatitis (MASH); and CF602 for erectile dysfunction. Its technology platform utilizes the Gi protein coupled A3 adenosine receptor to target pathological cells with synthetic agonists to preserve normal cells. The company works in collaboration with pharmaceutical and biotechnology companies. Can-Fite is headquartered in Petah Tikva, Israel.
Headquarters
Israel
Address
P.O. Box 7537, 10 Bareket Street, Kiryat Matalon, Petah Tikva, 49170
Website
www.canfite.com
Telephone
972 3 9241114
No of Employees
5
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CANF (TLV)
Revenue (2024)
$405,000
-39.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-24.7%
(2024 vs 2023)
Market Cap*
$6.0M
Net Profit Margin (2024)
XYZ
-107.6%
(2024 vs 2023)
* As of and is in US$
Can-Fite BioPharma Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| CF602: Erectile Dysfunction |
| Piclidenoson (CF101): Psoriasis, Lowe sSndrome, Dog Osteoarthritis |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Can-Fite BioPharma Ltd | Johnson & Johnson | Eli Lilly and Co | Merck & Co Inc | Pfizer Inc |
|---|---|---|---|---|---|
| Headquarters | Israel | United States of America | United States of America | United States of America | United States of America |
| City | Petah Tikva | New Brunswick | Indianapolis | Rahway | New York City |
| State/Province | Petah Tikva | New Jersey | Indiana | New Jersey | New York |
| No. of Employees | 5 | 138,200 | 50,000 | 75,000 | 75,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Pnina Fishman, Ph.D. | Chairman; Chief Scientific Officer | Executive Board | 2023 | 76 |
| Motti Farbstein | Chief Executive Officer; Chief Operating and Financial Officer | Senior Management | 2023 | 62 |
| Zivit Harpaz | Director - Regulatory and Clinical Operations | Senior Management | - | - |
| Sari Fishman, Ph.D | Vice President - Business Development | Senior Management | 2017 | 53 |
| William D. Kerns | Vice President - Drug Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer